Alopecia Areata in Persons of Color: Understanding Unmet Patient Needs and Treatment Strategies
Released On
March 31, 2025
Expires On
March 31, 2026
Media Type
Internet
Completion Time
60 Minutes
Specialty
Dermatology, Pediatrics, Pharmacy, Primary Care
Topic(s)
Alopecia Areata
This activity is supported by an independent educational grant from Pfizer Inc.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
- Nurses — 1.0 ANCC Contact Hour
- Physican Associates — 1.0 AAPA Category 1 CME Credit
- Pharmacists — 1.0 ACPE Contact Hour
- CA-BRN — 1.0 CA-BRN Contact Hour for California nurses
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity was developed for dermatologists, pediatric dermatologists, dermatology nurse practitioners and dermatology physician associates, and other clinicians involved in the management of patients diagnosed with alopecia areata.
Program Overview
“It’s just hair loss,” doesn’t adequately describe the significant impact alopecia areata has on a patient’s appearance and self-esteem. The visible nature of the disease can lead to psychosocial effects such as stress, anxiety, depression, and social isolation. In this interactive, case-based activity, Brett King, MD, PhD, and Natasha Mesinkovska, MD, PhD, share their real-world experience treating patients with alopecia areata. They discuss the higher prevalence of alopecia areata in persons of color, psychological effects of the disease, diagnosis, and treatment approaches. Additionally, the efficacy, safety, and monitoring of JAK inhibitors are compared to other immunosuppressants, along with shared decision-making approaches, to provide patient-centered care.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the epidemiology of AA in persons of color
- Collaborate with the patient to develop a treatment plan to provide therapy to meet the goals of the persons of color with AA
- Incorporate tools into clinical practice to classify the severity of AA and monitor disease progression
- Recite the major warnings associated with the use of JAK inhibitors
Faculty
Brett King, MD, PhD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, Connecticut
Natasha A. Mesinkovska, MD, PhD
Associate Professor, Dermatology
UC Irvine School of Medicine
Irvine, California
Accreditation Statement
In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Credit
The Annenberg Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate Credit
The Annenberg Center has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until March 28, 2026. PAs should only claim credit commensurate with the extent of their participation.
Pharmacist Credit
The Annenberg Center designates this knowledge-based activity for a maximum of 1.0 hour. Credit will be provided to NABP CPE Monitor within 45 days after the activity completion.
Nurse Credit
The Annenberg Center designates this education for a maximum of 1.0 American Nurses Credentialing Center (ANCC) contact hour, including 0.75 pharmacology hour.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.0 contact hour. To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Disclosures of Conflicts of Interest
- Brett King, MD, PhD
- Advisory Board and Consultant: AbbVie, Almirall, AltruBio, Inc., Amgen, AnaptysBio, Apogee Therapeutics, Aquestive, Arena Pharmaceuticals, Aslan Pharmaceuticals, Bristol Meyers Squibb, Concert Pharmaceuticals Inc., Equillium, GSK, Horizon Therapeutics, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Lilly, Merck, Otsuka Pharmaceutical, Pfizer Inc, Q32 Bio Inc., Regeneron, Sanofi Genzyme, Soterios, Sun Pharmaceuticals, Takeda, TWi Biotechnology, Inc.
- Natasha A. Mesinkovska, MD, PhD
- Advisory Board: AbbVie, Armiral, Galderma, Johnson & Johnson, Lilly, Merck, Pfizer, Sun Pharmaceuticals
- Speakers Bureau: Lilly, Pfizer
The following have no relevant financial relationships to disclose:
Eugene Cullen, MD (Peer Reviewer)
Tim Drake, PharmD (Medical Writer)
Amber Lea Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
Annenberg Center for Health Sciences
All staff at the Annenberg Center have no relevant financial relationships to disclose.
All the relevant financial relationships listed for these individuals have been mitigated.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be available for download to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For help or questions about this activity please contact Continuing Education: [email protected]